Recent investigations have centered on the convergence of GLP|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopamine signaling. While GCGR activators are increasingly employed for treating type 2 T2DM, their emerging consequences on reinforcement circuits, specifically governed by DA pathways, are gaining substantial inter